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Abstract
Of 11 children with juvenile myelomonocytic leukemia (JMML) carrying RAS mutations (8, NRAS mutations; 3, KRAS2 mutations), 5 patients had a profound elevation in either or both the WBC and spleen size at diagnosis. Three patients had no or modest hepatosplenomegaly and mild leukocytosis at presentation, but subsequently showed a marked increment in spleen size with or without hematological exacerbation, for which non-intensive chemotherapy was initiated. The other 3 patients with NRAS or KRAS2 glycine to serine substitution received no chemotherapy, but hematological improvement has been observed during a 2-to 4-year follow-up. In the third group, all hematopoietic cell lineages analyzed had the RAS mutations at the time of hematological improvement, while DNA obtained from the nails had the wild type. Additionally, numbers of circulating granulocyte-macrophage progenitors were significantly reduced during the clinical course. Thus, some JMML patients with specific RAS mutations may have spontaneously improving disease.
Introduction
Somatic point mutations of the RAS (NRAS and KRAS2) genes at codons 12, 13, and 61 are found in about 20% of patients with juvenile myelomonocytic leukemia (JMML). 1, 2 Other patients show inactivation of NF1 or PTPN11 mutations. [3] [4] [5] While most patients with JMML die from progressive disease unless treated with hematopoietic stem cell transplantation, there are a few patients who have been reported to spontaneously recover without intervention. [6] [7] Some of these children have JMML associated with Noonan syndrome while others do not. So far, the individual prognosis in JMML carrying specific genetic aberrations remains unclear. We here report the clinical course in 11 patients with RAS mutations.
Materials and Methods

Cell Preparation
This study was approved by the Institutional Review Board of Shinshu University.
Informed consent was obtained from the guardians of the patients following institutional guidelines. We used the peripheral blood (PB) or bone marrow (BM) mononuclear cells (MNCs) that had been frozen with liquid nitrogen. CD3-and CD56-positive PB cells were separated immunomagnetically. 
Clonal cell culture
Twenty thousand PB or BM MNCs were plated in a dish containing methylcellulose medium supplemented with or without 0.01 to 10 ng/mL of granulocyte-macrophage colony-stimulating factor (GM-CSF). 9 To examine the clonal derivation of myeloid and erythroid lineages, two thousand CD34 + PB cells harvested immunomagnetically were cultured in methylcellulose medium supplemented with GM-CSF, stem cell factor, interleukin 3, and erythropoietin. Twelve days after incubation with 5% CO 2 , GM colonies, erythroid colonies, and mixed colonies were individually lifted, and prepared as single cell suspensions. Then, sequence analyses were performed on individual colony-constituent cells.
Detection of NRAS and KRAS2 mutations
DNA was extracted from PB or BM MNCs, and nails. Exon 1 (codons 12 and 13) and exon 2 (codon 61) of NRAS and KRAS2 genes were amplified by PCR, using primer pairs described previously. 10, 11 The PCR products were subjected to direct sequencing from both directions on an automatic DNA sequencer. (Cases 6 to 8) were modest at first presentation. However, a marked enlargement of spleen size was noted within 2 to 3 months after diagnosis in all 3 patients, followed by deterioration of leukocytosis in Case 7 and of anemia/thrombocytopenia in Case 8.
Results and discussion
Accordingly, oral 6-MP was administered to the three patients 3 to 9 months after diagnosis. In 3 patients (Cases 9 to 11), the hematological findings were similar to those of Cases 6 to 8 at first presentation. There was no significant change or a decrease of spleen size within 3 month of diagnosis in Cases 9 to 11, as shown in Figure   1A . Surprisingly, in these patients, hematologic improvement was observed over a two-to four-year follow-up, despite no chemotherapy. Thus, JMML patients carrying RAS mutations appear to be heterogenous with respect to the hematological progression.
As presented in Figure 1B , there was no significant difference in GM colony growth In Cases 9 to 11, DNA obtained from their nails had the wild type of the NRAS or KRAS2 gene, while hematopoietic cells had a point mutation. Thus, the three patients had a somatic and not germline Gly12Ser mutation in the RAS gene.
Niemeyer et al. 16 proposed age, platelet count, and HbF at diagnosis as factors for predicting the length of survival. Cases 9 to 11 were younger than 24 months of age, and had platelet counts of >33 x 10 9 /L and HbF of <15% at onset. On the other hand, Cases 6 to 8 also had no risk factors at diagnosis except for the HbF value in Case 6.
One possible parameter distinguishing between the two groups is change of spleen size within 3 month of diagnosis. Gly12Ser mutation in the RAS gene may be insufficient to confer the disease progression in JMML. Close followup is requisite, since these children still harbor a clonal oncogenic abnormality in their bone marrow.
In conclusion, no chemotherapy may be a recommended management for JMML patients with NRAS or KRAS2 glycine to serine substitution, but further large-scaled studies are needed to assess accurately the relationship between the mutational spectrum of the RAS gene and the disease phenotype.
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Cases 4 and 7 had a normal karyotype at presentation, but monosomy 7 approximately 3 years after diagnosis.
